Reuters logo
Novartis wins CHMP nod for drug combo against some lung cancers
February 24, 2017 / 1:23 PM / 10 months ago

Novartis wins CHMP nod for drug combo against some lung cancers

ZURICH (Reuters) - Swiss drugmaker Novartis’s (NOVN.S) drugs Tafinlar and Mekinist edged closer to approval in Europe to be used together against a type of lung cancer after a key committee on Friday published a recommendation to expand the combination’s indications.

The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland January 25, 2017. REUTERS/Arnd Wiegmann

The European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended Tafinlar in combination with Mekinist for adult patients with advanced non-small cell lung cancer (NSCLC) with a mutation. The EMA still must issue a final decision.

Novartis, whose combination competes with Roche’s (ROG.S) Cotellic and Zelboraf, said in a statement that its drugs will be the first targeted therapy for BRAF V600-mutated NSCLC patients if the EMA follows the recommendation, as is likely.

Reporting by John Miller; Editing by Michael Shields

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below